45 research outputs found
7: Long-term outcome of methotrexate-free GVHD prophylaxis using sirolimus and tacrolimus in matched related (MRD) and unrelated donor (URD) peripheral blood stem cell transplantation (PBSCT)
Elevated B cell activating factor (BAFF) in patient plasma after allogeneic stem cell transplantation is a potential biomarker for chronic graft versus host disease
31: Comprehensive Typing of 1143 Single Nucleotide Polymorphisms (SNP) in 220 Immunoregulatory Genes Demonstrates That Polymorphisms in CCL3, CCL4 and CCL27 Modulate the Risk of Acute Graft Versus Host Disease (GVHD)
Telomerase Activity in Regulatory T Cells is Inversely Associated With Severity of Chronic Graft-Versus-Host Disease (cGVHD) After Hematopoietic Stem Cell Transplantation (HSCT)
The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease